Atkinson J P, Schreiber A D, Frank M M
J Clin Invest. 1973 Jun;52(6):1509-17. doi: 10.1172/JCI107325.
Corticosteroids and splenectomy constitute two important therapeutic modalities in the treatment of autoimmune hemolytic anemia. Each of these may affect both the rate of synthesis of autoantibody and the clearance of antibody sensitized cells. The latter possibility has been examined in an experimental model which allows evaluation of the role of antibody and complement in the immune clearance of erythrocytes in molecular terms. The in vivo clearance of (51)Cr-labeled guinea pig erythrocytes sensitized with purified rabbit IgG or IgM antibody to produce a known number of complement-fixing sites per cell was studied. Corticosteroid therapy increased the survival of both IgG and IgM sensitized erythrocytes by decreasing sequestration in the reticuloendothelial system (RES). 5 days of therapy prior to injection of antibody coated cells were required for a maximal effect. It appeared that the RES of cortisone-treated animals had a lowered sensitivity to erythrocytes coated with antibody and complement and the cells were removed as though they were coated with fewer complement sites/cell. The general pattern and kinetics of clearance and the localization of sequestered cells were not modified by corticosteroids. As the number of IgG C1-fixing sites was increased, the difference betwen cortisone treated and control animals was less marked. Splenectomy led to an increased survival of IgG-coated cells and a sixfold increase in IgG C1-fixing sites was necessary in order to obtain similar rates of clearance in splenectomized and control animals. The liver was responsible for this much less efficient clearance of cells in splenectomized animals: the clearance pattern was typical of that noted for IgG. No effect at all was noted on the clearance of IgM sensitized cells in splenectomized animals. These experiments clearly demonstrate that both corticosteroid therapy and splenectomy act to decrease the in vivo clearance of IgG-sensitized cells: only corticosteroids alter the clearance of IgM-sensitized erythrocytes. This effect may be of major importance in explaining the efficacy of these therapeutic modalities in autoimune hemolytic anemia.
皮质类固醇和脾切除术是治疗自身免疫性溶血性贫血的两种重要治疗方式。它们各自可能会影响自身抗体的合成速率以及抗体致敏细胞的清除。后一种可能性已在一个实验模型中进行了研究,该模型能够从分子层面评估抗体和补体在红细胞免疫清除中的作用。研究了用纯化的兔IgG或IgM抗体致敏的(51)Cr标记豚鼠红细胞在体内的清除情况,以使每个细胞产生已知数量的补体结合位点。皮质类固醇治疗通过减少在网状内皮系统(RES)中的扣押来提高IgG和IgM致敏红细胞的存活率。在注射抗体包被细胞之前进行5天的治疗才能达到最大效果。似乎可的松治疗动物的RES对抗体和补体包被的红细胞敏感性降低,并且这些细胞的清除方式就好像它们每个细胞的补体结合位点较少一样。皮质类固醇并未改变清除的总体模式和动力学以及扣押细胞的定位。随着IgG C1结合位点数量的增加,可的松治疗动物与对照动物之间的差异变得不那么明显。脾切除术导致IgG包被细胞的存活率增加,并且为了在脾切除动物和对照动物中获得相似的清除率,IgG C1结合位点需要增加六倍。在脾切除动物中,肝脏对细胞的这种清除效率较低:清除模式是IgG所特有的。在脾切除动物中未观察到对IgM致敏细胞清除的任何影响。这些实验清楚地表明,皮质类固醇治疗和脾切除术均起到降低IgG致敏细胞体内清除率的作用:只有皮质类固醇会改变IgM致敏红细胞的清除。这种效应在解释这些治疗方式在自身免疫性溶血性贫血中的疗效方面可能具有重要意义。